• Keine Ergebnisse gefunden

Table S-1. Distribution of care strategies for localized prostate cancer of various risksDetected byCare strategy Distribution SourceManaging low-risk localized prostate cancer

N/A
N/A
Info
Herunterladen
Protected

Academic year: 2022

Aktie "Table S-1. Distribution of care strategies for localized prostate cancer of various risksDetected byCare strategy Distribution SourceManaging low-risk localized prostate cancer"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Jetzt herunterladen ( 1 Seite )

Volltext

(1)

Table S-1. Distribution of care strategies for localized prostate cancer of various risks

Detected by Care strategy Distribution Source

Managing low-risk localized prostate cancer

MRI targeted biopsy Watchful waiting 13% Survey of local experts

Active surveillance 63%

Active treatment 25%

Systematic biopsy Watchful waiting 19%

Active surveillance 53%

Active treatment 28%

Managing intermediate-risk localized prostate cancer

MRI targeted biopsy Watchful waiting 17% Survey of local experts

Active treatment 83%

Systematic biopsy Watchful waiting 13%

Active treatment 87%

Managing high-risk localized prostate cancer

MRI targeted biopsy Watchful waiting 3% Survey of local experts

Active treatment 97%

Systematic biopsy Watchful waiting 6%

Active treatment 94%

Note:

1. MRI targeted biopsy refers to the administration of MRI targeted biopsy combined with systematic biopsy following a positive mpMRI.

Referenzen

Jetzt herunterladen ( DOCX - 1 Seite - 25.03 KB )

ÄHNLICHE DOKUMENTE

Electrospray Mediated Localized and Targeted Chemotherapy in a Mouse Model of Lung Cancer.

In the current study, we investigate the effect of electrospray mediated localized chemotherapy using Cisplatin on the mice subcutaneous tumor model of lung adenocarcinoma in

Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.

While moderate hypofractionation (2.2–4 Gy) has been proven to be non-inferior to normal fractionation in several large randomized trials for localized prostate cancer, level I

Table S-2. Distribution of treatments for metastatic cancer and castration-resistant prostate cancerManaging metastasisUse of careDosing regimenSourceFirst-line therapy for metastatic cancer

Docetaxel + cabazitaxel 2% Docetaxel with cabazitaxel 20mg per square meter of body surface area every 3 weeks for 10 cycles Docetaxel + abiraterone 7% Docetaxel 75mg per square

Table S-5. Distribution of patients with localised prostate cancer across risk statusISUP gradegroupingRisk statusProportion of patients with localisedprostate cancer with this risk statusSource

[r]

Probability of detecting low-risk given true intermediate-risk cancer using MRI targeted biopsy as first biopsy 0.08 (0.06

Parameters that are highlighted indicate that the upper bound limit of the parameter led to a lower ICER;2. parameters that are not highlighted indicate that the upper bound limit

The impact and collateral damage of COVID‑19 on prostate MRI and guided biopsy operations: Society of Abdominal Radiology Prostate Cancer Disease‑Focused Panel survey analysis

Finally, the impact of COVID-19 was seen not only on clinical operations but also on research efforts, with approxi- mately half of the survey participants responding that there has

Comparison of MRI, PET, and 18F‑choline PET/MRI in patients with oligometastatic recurrent prostate cancer

Conclusion FCH PET/MRI has a higher detection rate than MRI or PET alone for PCa patients with OMD and PSA lev- els > 0.5 ng/mL, prompting a better choice of treatment.. Keywords

External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high‑risk clinically localized prostate cancer

Background We aimed to establish an external validation of the Briganti 2019 nomogram in a Japanese cohort to preopera- tively evaluate the probability of lymph node invasion